Low levels have been associated with myocardial infarction, atherosclerosis, hypertrophy, hypertension, and impaired ventricular function [9,12-18], whereas paradoxically high levels in CAD patients have been linked to increased cardiovascular and all-cause mortality, a phenomenon termed the “adiponectin paradox,” particularly evident in advanced heart failure [17-19]. Here, ADIPOQ is linked to myocardial infarction.